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Toll-like receptor 3 (TLR3) can signal the production of a suite of cytokines and chemokines in response to
double-stranded RNA (dsRNA) ligands or the dsRNA mimic poly(I-C). Using a human embryonic kidney 293T
cell line to express human TLR3, we determined that poly(I-C)-induced signal could be significantly inhibited
by single-stranded DNAs (ssDNAs), but not ssRNA or dsDNA. The ssDNA molecules that down-modulated
TLR3 signaling did not affect TLR4 and do not require the hypomethylated CpG motif found in TLR9 ligands.
The degree of modulation can be altered by the length, base sequence, and modification state of the ssDNAs.
An inhibitory ssDNA was found to colocalize with TLR3 in transfected cells and in a cell line that naturally
expresses TLR3. The inhibitory ssDNAs can compete efficiently with dsRNA for binding purified TLR3
ectodomains in vitro, while noninhibitory nucleic acids do not. The ssDNAs also decrease the levels of several
cytokines produced by the human bronchial epithelial cell line BEAS-2B and by human peripheral blood
mononuclear cells in response to poly(I-C) stimulation of native TLR3. These activities indicate that ssDNAs
could be used to regulate the inflammatory response through TLR3.
The types and amounts of cytokines produced can dictate
the outcome of pathogen infection and are responsible for
inflammation-associated diseases, including colitis, asthma,
psoriasis, and septic shock (13, 26, 39). The ability to modulate
cytokine production is an important therapeutic approach for
treating these conditions.
Innate immune receptors are promising targets to regulate
the complex cascade of events that lead to cytokine production
(1). These receptors recognize pathogenic and endogenous
ligands through their molecular signatures and then use several
signaling pathways to alter gene expression. The Toll-like re-
ceptors (TLRs) are a family of structurally related class I sin-
gle-pass transmembrane proteins that serve as the sentries for
pathogen infections (9, 14, 38). At least 11 TLRs have been
identified in the mammalian genome and are classified accord-
ing to the ligands that initially activate TLR-dependent signal-
ing, including highly conserved pathogen proteins, cell wall
components, and nucleic acids (8, 27).
Four TLRs can respond to nucleic acids. TLR7 and TLR8
recognize single-stranded RNAs (ssRNAs) (1, 15, 38); TLR9
recognizes ssDNA molecules that contain hypomethylated
CpG motifs (4, 25); and TLR3, the focus of this study, recog-
nizes double-stranded RNAs (dsRNAs) (2). The activation of
TLR3 by ligands can lead to the nuclear translocation of the
transcription factor NF-B, conferring changes in gene expres-
sion (10, 21, 34). In laboratory studies, poly(I-C), a synthetic
dsRNA analog, has served as a TLR3 ligand (30). Poly(I-C)
stimulation of TLR3 can be assayed by using a luciferase re-
porter driven by NF-B promoter elements (10, 34, 37). The
effects of TLR3 could also be monitored by assessing the
amounts of cytokines and chemokines produced by poly(I-C)-
induced cells (20).
How TLR3 interacts with its ligand is not completely under-
stood. In vitro, TLR3 can bind poly(I-C), a potent TLR3
agonist that is a dsRNA mimic. Recent models favor direct
contact between TLR3 and poly(I-C) through an asparagine-
rich surface in the TLR3 ectodomain (3ECD) (6, 34). Binding
is also improved at lower pHs (6, 10, 34, 37), an observation
that has led to the model that higher-affinity ligand binding by
TLR3 may take place within the confines of acidic vesicles,
sites where TLR3 is primarily localized (30). Ligand binding
and the subsequent oligomerization of TLR3 will activate the
TRIF adaptor, eventually leading to signaling by the NF-B
transcription factor (23).
Several TLRs can also regulate each other’s signaling either
through heterodimerization or through cross talk mediated by
ligands and/or signaling molecules. ssDNA ligands containing
an unmethylated CpG motif, such as oligodeoxynucleotide
2006 (ODN2006) (15, 16), are agonists for TLR9. Furthermore,
ssDNAs have been reported to enhance the activation of murine
chemokine and cytokine expression through the poly(I:C)-
mediated pathway (3, 32). Unlike TLR3, TLR9 activation in-
volves the MyD88 adaptor, also leading to NF-B activation
(4). We show that ssDNAs inhibited poly(I-C)-mediated TLR3
signaling in two human cell lines, unlike the enhancement
observed in murine cells. Furthermore, the ssDNA also inhib-
ited cytokine production in human peripheral blood mononu-
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clear cells (PBMCs). This effect is unrelated to TLR9 since
ssDNAs that do not activate TLR9 nonetheless have potent
inhibitory activity against the TLR3 pathway.
MATERIALS AND METHODS
Reagents. ODN2216, ODN2216c, ODN2006, and ODN2006c were purchased
from InvivoGen (San Diego, CA) or synthesized by Invitrogen (Carlsbad, CA).
The sequence of ODN2216 is 5-ggG GGA CGA TCG TCg ggg gg-3. The
sequence of ODN2216c is 5-ggG GGA GCA TGC TGg ggg gc-3. The sequence
of ODN2006 is 5-tcg tcg ttt tgt cgt ttt gtc gtt-3. The sequence of ODN2006c is
5-tgc tgc ttt tgt gct ttt gtg ctt-3. The bases in capital letters form phosphodi-
esters, and those in lowercase form phosphorothioates. Other chemically syn-
thesized deoxyoligonucleotides were made by IDT (Coralville, IA). Poly(I-C)
was purchased from GE Amersham (Piscataway, NJ) and reconstituted in phos-
phate-buffered saline (PBS) while being heated at 50°C. Lipofectamine 2000 was
purchased from Invitrogen, Inc. Dual-Glo luciferase assay system reagents and
plasmid phRL-TK were purchased from Promega Corp. (Madison, WI). Plas-
mids pNiFty-Luc and pUNO-hTLR3 were purchased from InvivoGen. The an-
tibody specific to TLR3 (AF1487) was purchased from R&D Systems (Minne-
apolis, MN). The antibody specific to TLR3 used to stain cells in microscopy
experiments was purchased from eBioscience. Unless stated otherwise, all me-
dium components were purchased from Invitrogen or Sigma (St. Louis, MO).
Ficoll-Paque Plus solution was purchased from GE Amersham or Invitrogen. A
custom human 14-plex cytokine kit was purchased from Invitrogen, Inc.
Human TLR3 luciferase reporter assay. Human embryonic kidney (HEK)
293T cells were harvested from an actively growing culture and plated in CoStar
white 96-well plates at 4.4  104/ml for transfection. When the cells were 85 to
90% confluent, they were transfected with a mixture of Lipofectamine 2000 and
plasmids pNiFty-Luc, pUNO-huTLR3, and phRL-TK that, respectively, code for
the firefly luciferase reporter, full-length wild-type TLR3, and the Renilla lucif-
erase transfection control. The cells were allowed to incubate for 24 h to allow
expression from the plasmids. Poly(I-C) (2.5 g/ml) was then added to appro-
priate sets of transfected cells to induce TLR3-dependent NF-B activity. After
another 24 h of incubation, the cells were harvested by using a Dual-Glo lucif-
erase assay (Promega Corp.). Luminescence was measured by using a FLUOstar
OPTIMA plate reader (BMG Labtech, Inc.). The data are usually presented as
either a ratio, which was derived by dividing the results for NF-B firefly lucif-
erase in relative light units by the results for the control Renilla relative light
units, or a determination of the level of induction, in which all treatment group
luciferase ratios were divided by the luciferase ratio for unstimulated TLR3-
transfected cells.
The TLR4 assay was performed similarly to the TLR3 assay except that
pUNOTLR4, along with its cofactors pUNOCD14, pUNOMD2, and
pUNOLBP, was used instead of the TLR3 plasmid.
Cytokine production by BEAS-2B cells. BEAS-2B cells were grown in LHC-9
medium (Invitrogen). Cells were plated at 1 106/ml and 200 l/well in collagen-
coated 96-well plates (BD Biosciences). Cells were allowed to attach for 4 to 6 h
before stimulation with 25 ng/ml poly(I-C) in the presence or absence of oligo-
nucleotide. Supernatants were collected after 24 h and stored at 20°C until
measurement of cytokine secretion by using a custom multiplex Luminex kit
(Invitrogen). Sample acquisition and analysis were performed by using a Lumi-
nex 100 IS (Luminex Corp., Austin, TX) with StarStation software (Applied
Cytometry Systems, Inc., Sacramento, CA).
Assays with human PBMCs. Human PBMCs were isolated from whole blood
collected from healthy donors. All necessary permissions, approvals, and li-
censes, including approval by a relevant third-party Institutional Review Board
(IRB) of an informed consent form and protocol and any relevant study-related
documentation required by the IRB, are collected and maintained for the sourc-
ing, handling, storage, banking, transport, or use of biological samples from
employee volunteers at Centocor, R&D, Inc. Blood was collected into CPT
vacutainers containing heparin (BD Biosciences), which were centrifuged at
1,500  g for 15 min at room temperature. The entire layer above the gel was
collected into a 50-ml conical tube. The conical was filled with Hanks balanced
salt solution and spun at 300  g for 15 min. The cells were washed once more
with Hanks balanced salt solution. After the final wash, the pellet was resus-
pended in complete medium: RPMI 1640 medium with Glutamax-1TM, 10%
FBS, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 10 g/ml gen-
tamicin. An aliquot of the cells was removed and mixed with 50 g/ml trypan
blue to obtain a live-cell count. The cells were plated in 96-well plates at a
concentration of 1  106 cells/well (0.2 ml/well).
Poly(I-C) or ssDNAs used in the analysis of cytokine/chemokine production
were added to the cells simultaneously. The ssDNAs were reconstituted in water
before use. Supernatants from cells were harvested after 24 h and frozen at
20°C until all of the samples were ready for quantification of cytokines. Cyto-
kine levels were measured by using Luminex technology and a custom human
14-plex kit (Invitrogen).
Western blots. 293T cells expressing TLR3 and treated with various nucleic
acids were lysed with passive lysis buffer (Promega, Inc.) and sonicated to de-
grade chromosomal DNA. Equal amounts of proteins from each sample, as
determined by staining with Coomassie blue, were separated on NuPAGE 4 to
12% bis-Tris gels and blotted onto polyvinylidene difluoride membrane. The
anti-TLR3 antibody AF1487 from R&D Systems was used as primary antibody
for Western analysis. The blots were developed with peroxidase-conjugated
secondary antibodies and an ECL-plus Western-blotting detection system. Sam-
ples from the 3ECD secretion assay were collected as follows. Amounts of 1 
105 HEK 293T cells were transfected with plasmid pBETH-3ECD (33) by using
Lipofectamine as described above. The medium was removed 24 h later and
replaced with 500 l Dulbecco’s modified Eagle’s medium or Dulbecco’s mod-
ified Eagle’s medium containing ssDNAs. Twenty-four hours later, the medium
was harvested and the cells lysed with the passive lysis buffer. Both the medium
and the cell lysate were subjected to Western analysis.
Biochemical analysis of TLR3 ECD binding to nucleic acid. A recombinant
3ECD containing amino acid residues 27 to 704 was expressed and purified in
293T cells and used for the cross-linking assay (37). ODN2006 and IC18 were
end labeled by using T4 polynucleotide kinase and [-32P]ATP. A standard
cross-linking reaction mixture used a mixture of 3ECD (200 ng) with and without
competitors in buffer X containing 50 mM sodium acetate (pH 5.6), 50 mM
NaCl, and 4 mM MgCl2. Cross-linking was performed for 2 min at 3,600 J/cm2.
The reaction mixture was separated in a 4 to 12% denaturing protein gel.
Biotinylated ODN2006 was bound to streptavidin resin overnight in buffer X.
A 30-l slurry of resin containing approximately 3 g of biotinylated ODN2006
was mixed with 3 g of 3ECD and 3 g of bovine serum albumin (BSA) in the
presence or absence of 3 g of competitors (unless otherwise mentioned) and
incubated on ice for 5 h or at room temperature, as specified. The unbound
fraction was removed by centrifugation, and the pellet washed with the same
buffer as described above. The final pellet was resuspended in 15 l of sodium
dodecyl sulfate-polyacrylamide gel electrophoresis loading buffer and separated
on 4 to 12% denaturing protein gel along with the unbound fraction, followed by
staining with Coomassie blue. This experiment yielded reproducible results in
three independent assays.
Fluorescence microscopy. Poly(I-C) was labeled with fluorophore by using a
Cy5 labeling kit as recommended by the manufacturer (Mirus Bio Corp.). HEK
293T cells were transiently transfected with a pcDNA plasmid encoding wild-type
TLR3 by using Lipofectamine 2000. Following a 24-h incubation, the medium
was replaced and cells were seeded onto 12-mm coverslips coated with rat tail
collagen I (BD Biosciences, San Diego, CA). After a 24-h incubation, the cells
were either treated with 2 M of ODN2006 modified at the 3-end with fluo-
rescein isothiocyanate (FITC) (ODN3F) (InvivoGen) or left untreated for 24 h.
All cells on coverslips were then gently washed with PBS, transferred to wells
containing 4% paraformaldehyde diluted in PBS, and fixed for 30 min at room
temperature. After two washes in PBS containing 0.05% Tween 20 (PBST), the
cells were permeabilized for 15 min with 0.1% TX-100 diluted in PBS, washed
once more, blocked for 30 min with Image-iTFX signal enhancer (Invitrogen),
and further blocked for an additional 2 h at room temperature with 1 blocking
buffer (Sigma). The permeabilized and fixed cells were incubated with a goat
anti-human TLR3 antibody (3 g/ml; eBioscience), diluted in blocking buffer
overnight at 4°C, and then washed four times with PBST and incubated for 1 h
at room temperature with Alexa Fluor 647-conjugated donkey anti-goat immu-
noglobulin G (2 g/ml; Invitrogen) containing 1 g/ml of 4,6-diamidino-2-
phenylindole (DAPI; Sigma) diluted in 1 blocking buffer. The coverslips were
next carefully washed an additional four times in PBST, followed by one wash in
distilled water, inverted, placed on microscope slides containing Citifluor mount-
ing medium (Ted Pella), and sealed with nail polish. Cells were imaged by using
a 60 oil immersion objective (numerical aperture, 1.4), and optical slices of 0.2 m
were captured by using an UltraView ERS confocal microscope (Perkin Elmer).
FACS analysis. Fluorescence-activated cell sorter (FACS) analyses were per-
formed with 293T cells grown in six-well collagen-coated plates (BD Biosciences)
at a concentration of 2  106 cells/well. The cells were transfected with 1 g of
the appropriate plasmids by using Lipofectamine 2000 (Invitrogen). The staining
of cell surface-associated TLR3 used cells that were harvested 24 h after trans-
fection and washed twice with ice-cold FACS buffer (1 PBS containing 10 mM
phosphate, 150 mM NaCl, pH 7.4, 3% fetal bovine serum, 0.04% sodium azide)
before suspension at2 107 cells/ml in FACS buffer. The cells were stained for
30 min at 4°C with 1 g of phycoerythrin-labeled anti-human TLR3 monoclonal
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antibody (MAb) (clone TLR3.7; eBioscience, San Diego, CA) or a negative-
control mouse immunoglobulin G1 antibody. The antibodies were added to
aliquots of the cells in 96-well plates and incubated for 30 min on ice in the dark.
The cells were washed twice with FACS buffer to remove unbound antibody and
then resuspended in FACS buffer. Viaprobe (BD Biosciences) was added to the
cultures to exclude dead cells. The cells were transferred to the appropriate tubes
and analyzed by using a FACSCalibur machine (BD Biosciences).
RESULTS AND DISCUSSION
ssDNAs can inhibit the poly(I-C) induction of TLR3 in an
NF-B reporter assay. In examining whether ligands of TLR3
and TLR9 can influence their respective activities, we added a
mixture of poly(I-C) and ODN2006 to reporter assays in tran-
siently transfected HEK 293T cells, a cell line that has low
levels of these receptors (2, 4). This ligand combination did not
obviously affect TLR9 activity but significantly reduced NF-B
activity in cells expressing TLR3 (Fig. 1A). Furthermore, the
inhibition of TLR3-dependent reporter activity was a function
of the concentration of ODN2006, with 50% inhibition being
observed at 0.1 M of ODN2006 and the NF-B signal
FIG. 1. Single-stranded oligonucleotides can inhibit TLR3 activation of signaling. (A) ODN2006 inhibited the TLR3-dependent activation of the
firefly luciferase reporter activity driven by the NF-	 promoter, as well as that driven by the IFN-stimulated gene 56 (ISG56) and IFN-stimulated
responsive element (ISRE) promoters. The sequence of the fully phosphorothioated ODN2006 is shown above the graph. Plasmids used to express TLR3
and TLR9 are in the pUNO vector that is driven by a human EF1/human T-cell leukemia virus promoter. (B) ODN2006 can inhibit TLR3 activation
of the NF-B luciferase activity in a concentration-dependent manner. Inset shows that the addition of ODN2006 or another ssDNA did not affect the
level of TLR3 expression, as determined by Western blotting using a monoclonal antibody (AF1487) from R&D Systems directed to 3ECD. “V” indicates
a sample transfected with the empty vector. (C) Other single-stranded ODNs can also inhibit TLR3 activation of the NF-B reporter activity.
(D) Signaling by TLR4 and its coadapters was not sensitive to the presence of several ssDNAs. “Mock” indicates the addition of naı¨ve medium. TLR4
was induced by the addition of lipopolysaccharide at 1g/ml. mTLR4, murine TLR4; 75m, 75-mer. Each bar represents the mean of the results for activity
in six independent luciferase assays, and 1 standard error is reported above the bars. The level of activity was calculated as follows. The ratio of the signals
from firefly luciferase over Renilla luciferase (internal control driven from a constitutive promoter) in cells induced with poly(I-C) (final concentration,
2.5 g/ml) was divided by the ratio of the signals from an uninduced sample. pIC, poly(I-C); 2006, ODN2006; , present; , absent.
TABLE 1. A summary of the effects of mutations in TLR3 on
inhibition by ODN2006
Description of TLR3
protein
Amt (M) of
ODN2006 used
Activity
(%) (SE)
Wild-type TLR3 0 100 (1)
Wild-type TLR3 0.2 13 (2)
K89A 0 87 (2)
K89A 0.2 12 (2)
L412F 0 38 (1)
L412F 0.2 12 (2)
E442A 0 61 (2)
E442A 0.2 10 (2)
N515A 0 42 (1)
N515A 0.2 9 (1)
R544A 0 87 (4)
R544A 0.2 23 (4)
R331A K418A 0 84 (6)
R331A K418A 0.2 13 (2)
R394A K418A 0 52 (3)
R394A K418A 0.2 13 (1)
R331A R394A K418A 0 70 (5)
R331A R394A K418A 0.2 14 (2)
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equivalent to background at 2 M (Fig. 1B). The inhibitory
effects were also observed in cells transfected with different
amounts of the TLR3 expression plasmids and with a number
of TLR3 mutants that are partially defective due to amino acid
substitutions in the ligand binding and/or dimerization do-
mains (Table 1; data not shown) (34). Similar levels of inhibi-
tion were also observed with luciferase reporter constructs
driven by the beta interferon (IFN-	), IFN-stimulated gene 56,
and IFN-stimulated responsive element promoters, all of
which can respond to TLR3 (Fig. 1A).
The ability of ODN2006 to inhibit TLR3 signaling was spe-
cific, as single-stranded poly(I), poly(C), and poly(U) all re-
tained 70% or more of the level of TLR3 activity induced by
poly(I-C) with wild-type TLR3 (Table 2). Plasmid DNAs and
the dsRNA mimic poly(I-U) also did not significantly affect
TLR3 activity. A 54-bp dsDNA at 0.2 M (6.6 g/ml) final
concentration resulted in only a 15% reduction of TLR3 ac-
tivity, in contrast to the sevenfold inhibition seen with 0.2 M
of ODN2006. These results demonstrate that ODN2006 can
specifically inhibit the TLR3 pathway in comparison to the
inhibition of the TLR3 pathway by other nucleic acid moieties.
To determine whether the inhibition of TLR3 activity was
due to an effect on TLR3 expression, Western blot analysis was
performed in the presence of various ligands (Fig. 1B, inset).
None of the ligands significantly affected TLR3 protein levels,
indicating that the inhibitory effect of ODN2006 on TLR3 is
not at the level of TLR3 expression.
To determine if the TLR3 inhibitory effect is specific to
ODN2006 and related to the activity of TLR9, we tested sev-
eral other TLR9 stimulatory and nonstimulatory ssDNAs (Fig.
1C). ODN2006c has the internal CpG dinucleotide of
ODN2006 replaced by a GpC, a change which is associated
with a loss of TLR9 activation (4). ODN2216 is a type A
human TLR9 ligand, while the variant ODN2216c contains a
substitution in the CpG motif that renders ODN2216 a non-
functional ligand of TLR9 (4). All four ssDNAs inhibited
TLR3 to a similar extent (Fig. 1C), suggesting that the inhibi-
tion is not specific to the CpG sequence that characterizes
TLR9 ligands and antagonists. These results demonstrate that
the ability of ssDNAs to inhibit TLR3 activity is not directly
related to signaling by TLR9.
To determine whether the ssDNAs can inhibit signaling by
an unrelated TLR, we assessed their effects on TLR4. A 20-
fold activation of the NF-B promoter-driven luciferase re-
porter was observed in 293T cells transfected with plasmids
expressing TLR4 and its coreceptors (CD14, MD2, and LBP)
and induced with lipopolysaccharide 24 h after transfection
(Fig. 1D). Several ssDNA inhibitors of TLR3 did not signifi-
cantly affect TLR4-dependent luciferase production (Fig. 1D),
and the lack of any observable effect on TLR4 signaling argues
against TRIF being a target of inhibition by the ssDNAs, al-
though it remains possible that TLR4 can signal through an
MyD88-dependent pathway in our assay (22, 39).
Properties of inhibitory ssDNAs. To address whether the
inhibitory activities of the ssDNAs require unmodified 5 and
3 termini, ODN2006 was synthesized with either a 5 Cy5
modification, resulting in a molecule named ODN5C, or the
modification forming ODN3F. Both dyes are bulky in com-
parison to nucleotides, and an FITC attached to the 5 termi-
nus of a CpG-containing oligonucleotide is known to prevent
its recognition by TLR9 (40). Both ODN5C and ODN3F
FIG. 2. Properties of the ssDNAs needed to inhibit poly(I:C)-de-
pendent TLR3 activation of reporter expression. (A) Fluorescent dyes
attached to the 3 or 5 terminus of ODN2006 did not affect the
inhibitory activity of ODN2006. These molecules were added to the
cells at a final concentration of 1 M, while poly(I-C) was added at 2.5
g/ml. The numbers above the bars show the mean levels of induction
for all of the independent trials, and the error bars show the range for
1 standard error. “Mock” indicates control media. (B) Comparison of
the inhibitory properties of fully phosphorothioated ODN2006 and
derivatives that vary only in the number of phosphorothioates. All
ODNs were used at 2 M. pIC, poly(I-C). (C) Correlation between the
length of the unmodified ssDNAs and their inhibitory activity against
TLR3-dependent activation of NF-B reporter. All of the oligonucle-
otides used in this graph contained only phosphodiesters and were
used at 2 M. The sequences of the oligonucleotides are shown in
Table 3. 2006, ODN2006.
TABLE 2. dsDNA and ssRNAs are unable to inhibit TLR3 signaling
Ligand or expression
plasmid (g/ml)a Form
Amt (g/ml)
of poly(I-C)
used
TLR3 activityb
(%)
None None 15
None 2.5 100 (7)
Plasmid A (12.5) dsDNA 2.5 114 (9)
Plasmid A (25) dsDNA 2.5 100 (9)
Plasmid B (12.5) dsDNA 2.5 102 (3)
Plasmid B (25) dsDNA 2.5 114 (17)
54-bp DNA (6.6) dsDNA 2.5 83 (9)
54-bp DNA (17) dsDNA 2.5 63 (5)
Poly(I) (12.5) ssRNA 2.5 78 (3)
Poly(I) (25) ssRNA 2.5 75 (9)
Poly(C) (12.5) ssRNA 2.5 2.5 91 (22)
Poly(C) (25) ssRNA 2.5 2.5 78 (13)
Poly(U) (12.5) ssRNA 2.5 2.5 110 (9)
Poly(U) (25) ssRNA 2.5 2.5 109 (4)
Poly(I-U) (12.5) ssRNA 2.5 76 (3)
Poly(I-U) (25) ssRNA 2.5 73 (5)
a Plasmid A, 6.5-kb pcDNA-derived plasmid; plasmid B, 9.0-kb pcDNA-de-
rived plasmid; none, no ligand or plasmid added.
b Data are the means of the results of five sets of experiments. The numbers in
parentheses denote 1 standard error.
4510 RANJITH-KUMAR ET AL. MOL. CELL. BIOL.
 o
n
 Septem
ber 12, 2018 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
inhibited TLR3 signaling, indicating that unmodified termini
of ODN2006 are not required to inhibit TLR3 (Fig. 2A). This
feature also differs from the recognition of ssDNA by TLR9,
which requires an unblocked 5 terminus in the ligands.
ODN2216 and ODN2006 had, respectively, 6 or all 23
phosphodiester groups replaced with phosphorothioates.
We examined whether phosphorothioates are necessary for
the inhibitory activities of ssDNAs. A phosphodiester ver-
sion of ODN2006 (named dODN) was unable to inhibit TLR3
(Fig. 2B), suggesting that phosphorothioates contribute to the
ability to inhibit TLR3. ODN1PT, with phosphorothioates only
at the two termini, and ODN3PT, with three phosphorothio-
ates each at the two termini, had inhibitory activity against
TLR3 signaling that was improved in comparison to the activ-
ity of dODN (Fig. 2B). These results indicate that while phos-
phorothioates in ODN2006 can contribute to TLR3 inhibition,
not all of the phosphodiesters need to be modified (Fig. 2B).
Phosphorothioates can increase DNA stability in cells (36).
If the potent inhibitory effect of ODN2006 is due to its stability,
we reasoned that some unmodified ssDNAs should be inher-
ently more resistant to degradation due to their structure in
solution and/or their length. To test this prediction, a panel of
unmodified ssDNAs that varied in sequence and length from
19 to 75 nucleotides (nt) were tested at 2 M (Fig. 2C and
Table 3). A range of TLR3 inhibitory activity was observed.
Interestingly, the degree of inhibition correlated with the
length of the ssDNA, with those of 25 nt or less having no
obvious inhibitory activity (Fig. 2C). An examination of the
predicted structures of the oligonucleotides did not reveal an
obvious correlation to inhibitory activity (data not shown).
These results demonstrate that ssDNAs lacking phosphoro-
thioates can also inhibit TLR3 activity.
To address further the features required for ssDNAs to be
inhibitory against TLR3 signaling, we added six nucleotides to
either terminus of dODN (lacking phosphorothioates) to allow
for the formation of a hairpin clamp, resulting in an ODN
named HP1 (Table 4). We also tested two additional oligonu-
cleotides with clamps and lengths identical to those of HP1 but
with an internal sequence of either homopolymeric thymidy-
lates (HP2) or adenylates (HP3). While dODN was unable to
inhibit TLR3, HP1 reduced TLR3-specific signaling to 35%.
The effect of HP1 is not simply due to its length since HP2 and
HP3, of identical length to HP1, had only minimal effects on
TLR3 activity (Table 4). These results suggest that both the
stability of the oligonucleotide and its sequence contribute to
optimal inhibition of TLR3 signaling.
Functional relationship between ODN2006 and poly(I-C).
How do the ssDNAs affect TLR3 signaling? Several possibili-
TABLE 3. Correlation between oligonucleotide length and TLR3 inhibitory activity
Length
(nt) Sequence
NF-	 activitya
(%) (SE)
19 CCTTACCCATAATCAACTC 105 (8)
24 TTGGCCCTTACCCATAATCAACTC 86 (15)
25 GTCGACAAGGGATTGAACCTCGTTC 103 (8)
29 CAGTGTTGGCCCTTACCCATAATCAACTC 58 (6)
30 TACGTACTTAGATATGTCTTCAAACCATAC 67 (3)
34 CATAACAGTGTTGGCCCTTACCCATAATCAACTC 44 (3)
36 GGCTTCACTTTCATAGACTGCAACGGTGCCTGAAAG 38 (1)
39 ACAAACATAACAGTGTTGGCCCTTACCCATAATCAACTC 38 (1)
40 GCTCTAGATTAAGATTTACCGATGTCGCTCACTAAGGACC 32 (1)
41 AGTTCTAGACTACGTGACGACCTCCAGGTCAGCCGACATGC 35 (5)
43 ACAACTTAAATGTGGTTGGTGCCGATTCCTTTGCTTGGCTTCC 33 (1)
45 GAAGAACTGGATATCTTTGCCGCTTCATCTTTAAAAAAATTAGAG 47 (4)
53 AGTGCTAGCAGTCATCCAACAGAATCATGTCGATGTCCACTACATGGACAGGC 38 (4)
54 CAGTGCTAGCAGTCATCCAACAGAATCATGAATGGAATATTTGCTATTGAGAAG 36 (2)
56 AGTGCTAGCAGTCATCCAACAGAATCATGGCCCCCATCACGTACTCCACCTATGGC 22 (4)
57 AGTGCTAGCAGTCATCCAACAGAATCATGAGCACCTGGGTGCTGGTAGGCGGAGTCC 29 (2)
58 AGTGCTAGCAGTCATCCAACAGAATCATGGCCTCACACCTCCCTTACATCGAAGACGG 27 (4)
60 CTCGAGCAGAGGTCTCACACAGAGACAAGCGCATCAGTCAACAGAGATCCCTTGCGCTTC 35 (1)
75 GTCGACCACGGTTCTGCTACTTGTTCTTTGTTTTTCACCAACAAAATGGTATGGTTTGAAG
ACATATCTAAGTAC
30 (7)
a TLR3 activity obtained with poly(I-C) as the ligand was set at 100%.
TABLE 4. Unmodified oligonucleotides can inhibit TLR3 signaling
Oligonucleotide Sequence Amt (g/ml) ofpoly(I-C) used
TLR3
activitya
(%) (SE)
None None 20
None 2.5 100 (2)
ODN2006 TCGTCGTTTGTCGTTTTGTCGTT 2.5 22 (2)
HP1 CCGCCCTCGTCGTTTGTCGTTTTGTCGTTGGGCGG 2.5 35 (1)
HP2 CCGCCCTTTTTTTTTTTTTTTTTTTTTTTGGGCGG 2.5 80 (1)
HP3 CCGCCCAAAAAAAAAAAAAAAAAAAAAAAGGGCGG 2.5 110 (6)
a The numbers in parentheses denote 1 standard error. TLR3 activity obtained with poly(I-C) as the ligand was set at 100%.
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ties that are not mutually exclusive exist: (i) the ssDNAs could
affect TLR3’s distribution in the cell (30); (ii) the ssDNAs
could affect poly(I-C) uptake; (iii) the ssDNAs could bind to
TLR3 and prevent its binding to dsRNA; and (iv) the ssDNAs
could act on adaptors downstream of TLR3 signaling.
TLR3 can exist in two locations, the plasma membrane and
cytoplasmic endosomes (31). To examine a possible effect of
ODN2006 on TLR3 trafficking, the cell surface expression of
TLR3 in the presence of ssDNA was detected by FACS anal-
ysis of intact cells. No major difference in the abundance on
cells of surface-expressed TLR3, as detected by the fluores-
cence of an antibody recognizing TLR3, was found in the
presence or absence of ssDNAs (Fig. 3A). To examine traf-
ficking further, we used an assay for the secretion of 3ECD.
3ECD was documented as being secreted into the medium in
a process that likely mimics trafficking from the endoplasmic
reticulum to the plasma membrane (33). The presence of sev-
eral ssDNAs did not affect 3ECD secretion into the medium,
as detected by Western blots (Fig. 3B). In combination, we do
not have evidence in support of ODNs affecting the process of
TLR3 export to the plasma membrane.
Next, whether ODNs affect poly(I-C) uptake was examined
by manipulating the timing of the addition of ODN2006 and
poly(I-C). 293T cells transfected to express TLR3 were treated
by adding poly(I-C) to the medium at the same time as
ODN2006, adding poly(I-C) 8 h prior to the addition of
ODN2006, or adding them in the reverse order (Fig. 4A). The
level of NF-B activation was close to the background level
when ODN2006 was added simultaneously with poly(I-C) or
8 h prior to poly(I-C). However, when ODN2006 was added
8 h after poly(I-C) treatment, the NF-B-driven luciferase
activity was reduced by more than half. These results suggest
that ODN2006 can inhibit TLR3 activity even after poly(I-C)
has had an opportunity to induce TLR3 activity.
To delve deeper into whether ODN inhibition is related to
the poly(I-C) uptake, we examined whether the route of intro-
duction of ODN2006 would affect its ability to inhibit TLR3
(Fig. 4B). ODNs were either added to the culture medium or
transfected into cells by using Lipofectamine, and in both
cases, TLR3 was induced by adding poly(I-C) to the medium.
Both routes of introduction resulted in the inhibition of TLR3
signaling (Fig. 4B). In addition, neither route of introduction
had a significant effect on the secretion of 3ECD into the
culture medium (Fig. 4C). This result suggests that ODN2006
FIG. 3. Effects of ODNs on cell surface expression of TLR3 and
secretion of 3ECD. (A) FACS analysis of the cell-surface expression of
TLR3 in the presence of 1 M ODN2006. The oligonucleotide of 18
cytidylates (rC18) that does not affect TLR3 signaling was used as a
negative control. The times indicate the time the cells were fixed after
the addition of the oligonucleotides. All results are for three indepen-
dent samples, except for the 90-min time point at which we only had
enough culture wells for two independent trials. The results from the
two trials were within 10% of each other. 2006, ODN2006; MFI, mean
fluorescence intensity; s.e., standard error. (B) Secretion of 3ECD is
not affected by the addition of several different ssDNAs or poly(I-C) to
the cell medium. The bands are from Western blots of the medium or
the cell lysate probed with an MAb to TLR3 from R&D Systems. “
Inh.” denotes a reaction where a known inhibitor of 3ECD secretion
was added to the reaction mixture; pIC, poly(I-C); , present; ,
absent.
FIG. 4. Examination of the relationship between ODN2006 and
poly(I-C) and their effects on TLR3 signaling. (A) Effects of the order
of addition of poly(I-C) and ODN2006 on luciferase activity in trans-
fected HEK 293T cells. The times of addition are shown at the bottom
of the graph. (B) Comparison of the route of introduction and the
inhibitory effects of ODNs. The ligands were either added to the cell
culture medium (m-) or transfected into the cells by using Lipo-
fectamine (t-), as indicated. The means of the results are shown above
the bars, and the error bars show standard errors of the means.
(C) The secretion of 3ECD is not affected by the transfection of
ODN2006 or dODN into HEK cells. Where ODN2006 was used in the
absence of Lipofectamine (LF2K), it was added to the cell culture
medium. “V” indicates a sample transfected with the empty vector.
The upper band is the glycosylated 3ECD that was secreted into the
medium. The fainter lower band was found to be inside the cell (S.
Hoose, data not shown). pIC, poly(I-C); 2006, ODN2006; , present;
, absent.
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and poly(I-C) can both bypass any receptor at the plasma
membrane to affect TLR3 signaling. Scavenger receptor class
A has been identified as a receptor for the import of dsRNA,
including poly(I-C), in endothelial cells (29). The transport
function of scavenger receptor class A is thus not apparently
affected by treatment with ODN2006.
Last, we visualized the localization of Cy5-labeled poly(I-C)
in the presence and absence of ODN2006. In HEK 293T cells,
Cy5-poly(I-C) was found in punctate forms in the absence and
presence of TLR3 expression (see Fig. S1A in the supplemen-
tal material). However, this distribution was apparently not
affected in the presence of ODN2006. As reported in the
summary of the results in this section, we do not have evidence
that ODN2006 affects poly(I-C) uptake or trafficking.
ODN2006 can localize in endosomes. A third potential
mechanism of action for ssDNAs is that they can bind TLR3
and prevent its activation. A prediction of this model is that the
ssDNAs would localize at the sites of TLR3, endosomes that
can be marked by the location of the TLR3 ligand poly(I-C).
ODN3F was used as the ssDNA since it retained inhibitory
activity for TLR3. Poly(I-C) was labeled with Cy5 as described
in Materials and Methods, and the labeled poly(I-C) was de-
termined to be capable of activating NF-kB reporter expres-
sion in a TLR3-dependent manner (data not shown). The
distribution of ODN3F and poly(I-C) overlapped significantly
(Fig. 5A; see Fig. S1B in the supplemental material). These
results show that ODNs could traverse the membrane of HEK
293T cells to reach endosomes, consistent with previous re-
ports (17, 23). In addition, this result further suggests that the
ODN did not inhibit poly(I-C) uptake.
Next, we examined whether ODN3F can colocalize with
TLR3 in HEK 293T cells transfected to express TLR3 (Fig.
5B). ODN3F was added for 24 h and then fixed, permeabil-
ized, and stained with a TLR3-specific antibody in combination
with a fluorescently conjugated secondary antibody. As to be
expected in a transfection experiment, not all of the cells
expressed TLR3. In those that did, a majority of TLR3 was
localized to punctate spots indicative of intracellular vesicles
(Fig. 5B). ODN3F was also localized in punctate spots,
even in untransfected cells that did not express TLR3. How-
ever, in the cells expressing TLR3, the fluorescence from
ODN3F was coincident in numerous cases with the loca-
tions of TLR3 (Fig. 5B).
Since 293T cells express TLR3 from transfected plasmids,
we examined whether natively expressed TLR3 from a human
bronchial epithelial cell line (BEAS-2B) can colocalize with
FIG. 5. Colocalization of ODN2006 with TLR3. (A) Colocalization of the fluorescently labeled ODN2006 ODN3F with fluorescently labeled
poly(I-C). The three panels contain reconstructed confocal images of a typical field of transiently transfected HEK 293T cells. All three panels show
the locations of cellular nuclei stained with DAPI (blue). Fluorescent poly(I-C) was added to the cells to a final concentration of 5 g/ml, and
ODN3F was used at 2 M. In this panel, poly(I-C) is in red, while ODN3F is in bright green. Yellow denotes areas where the two signals merged.
(B) Colocalization of ODN3F with TLR3 in transfected HEK 293T cells. The upper panel shows cells stained for TLR3, as detected by a
fluorescently labeled secondary antibody. The bottom panel shows ODN3F localization in green. ODN3F was used at 2 M. The middle panel
contains a merged image representing the locations of TLR3 in red, the locations of ODN3F in bright green, and areas of colocalization in yellow.
(C) Colocalization of ODN3F with natively expressed TLR3 from a human lung epithelial cell line. Fluorescent poly(I-C) was added to the cells
to a final concentration of 2 g/ml, and ODN3F was used at 2 M. In this panel, ODN3F is red, poly(I-C) is bright green, and areas of
colocalization are yellow. pIC, poly(I-C); 
, anti; recomb., recombinant; endogen., endogenous.
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ODN3F added to the medium. Significant overlap in the flu-
orescence of TLR3 stained with fluorescently labeled MAb
and ODN3F was observed in punctate spots in the cytoplasm
of the BEAS-2B cells (Fig. 5C). These results are consistent
with a model in which the inhibitory effect of ODN2006 is due
to its binding to TLR3 either directly or indirectly through an
adaptor that is needed to transmit the signal from TLR3 or
both.
ODN2006 binding to 3ECD. The colocalization results are
consistent with the possibility that ssDNAs can bind TLR3.
ODN2006 could compete with poly(I-C) for the same binding
site, allosterically affect poly(I-C) binding, and/or alter the
consequence of TLR3 signaling in a manner independent of
poly(I-C).
To obtain a preliminary indication of whether TLR3 could
bind ssDNAs, we used a reversible cross-linking assay and
purified, recombinant 3ECD made in 293T cells (Fig. 6) (37).
This assay was previously used to map the RNA binding do-
main in the hepatitis C virus RNA polymerase and the severe-
acute respiratory syndrome coronavirus endoribonuclease (7,
24). Briefly, ODN2006-resin was cross-linked to 3ECD by us-
ing formaldehyde and then subjected to extensive digestion
with sequencing-grade trypsin. The unbound peptides were
saved for analysis. The resin was then washed extensively prior
to reversing the cross-linking with a 3-h treatment at 70°C. The
peptides in the bound and unbound fractions were then iden-
tified by mass spectrometry.
A number of peptides in the fraction eluted from ODN2006-
resin were enriched in comparison to the amounts of the un-
bound peptides (Fig. 6A). The majority of the peptides did not
match within 1 Da of the peptides expected from trypsin cleav-
age of the theoretical 3ECD, likely due to extensive modifica-
tion of the 3ECD produced in human cells (34). However, two
peptides were within 1 Da of the expected masses, a peptide of
relatively low abundance that corresponds to residues 211 to
222 of the 3ECD (P1) and a more highly enriched peptide
corresponding to residues 560 to 583 (P2) (Fig. 6B). The pres-
ence of multiple peptides indicates that ODN2006 could bind
to more than one region of 3ECD. However, P2 maps to the
asparagine-rich surface of 3ECD that has been demonstrated
to be critical for TLR3 function (34) and adjacent to residues
H539 and N541 that were previously demonstrated to contact
poly(I-C) (Fig. 6C) (6). These results show that ssDNAs can
bind to 3ECD, and the location of P2 suggests that ODN2006
can compete with poly(I-C) for binding TLR3.
To examine further how ssDNA can compete with poly(I-C)
FIG. 6. Initial mapping of the interaction between ODN2006 and 3ECD. (A) Identification of peptides derived from 3ECD that can be
reversibly cross-linked to ODN2006. The three mass spectra are of ions associated with the matrix, ions eluted from ODN2006-resin, and ions that
were not cross-linked to the resin. Regions of the spectra in the eluted peptides match to theoretical peptides P1 and P2 that were generated from
3ECD (red boxes). % Int, percentage of peak intensity. (B) Expanded views of the P1 and P2 spectra, along with the residues of the two peptides
assigned to these masses. (C) The locations of peptides P1 and P2 within the three-dimensional model of 3ECD (PDB accession number, 1ZIW).
The peptide spanning residues 211 to 222 is in green, and the one spanning residues 560 to 583 is in yellow. Red denotes the location of residue
H539, which has been identified as contacting dsRNA (6).
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for binding to 3ECD, we induced purified 3ECD binding with
5-radiolabeled ODN2006 by using UV irradiation. A parallel
reaction was performed with a radiolabeled 18-bp poly(I-C)
named IC18. Both ODN2006 and IC18 could be cross-linked
to 3ECD (Fig. 7A). While the same amounts of radiolabel and
ligand were used, issues such as radiolabeling efficiency make
it difficult to directly compare the cross-linking results. Also, it
is possible that an 18-bp poly(I-C) may be too small to bind
efficiently with TLR3 (28). Therefore, the relative cross-linking
to radiolabeled ODN2006 or IC18 was examined in the pres-
ence of 1- or 10-fold excesses of unlabeled versions of
ODN2006 and heterogeneous poly(I-C) that had lengths in
excess of 200 bp (Fig. 7A). Cross-linking to radiolabeled
ODN2006 was more resistant to challenge with heterogeneous
poly(I-C) than the reverse combination (Fig. 7A, compare
lanes 2 to 5 with 8 to 11), demonstrating that it is possible that
ODN could not only bind directly to 3ECD but could do so
with higher relative affinity than both poly(I-C) of the defined
length of 18 bp and heterogeneous poly(I-C) of a length that is
an efficient inducer of TLR3 signaling.
To examine the competition between ODN2006 and
poly(I-C) for interaction with TLR3, we examined whether
increasing concentrations of poly(I-C) (length, 200 bp) could
overcome the effects of ODN2006 in 293T cells (Fig. 7B). Cells
transfected to express TLR3 were treated with 2.5 to 20 g/ml
poly(I-C) with and without 0.2 M ODN2006. A four- to
eightfold-higher concentration of poly(I-C) resulted in only a
slight reduction in the inhibitory activity of ODN2006 (Fig.
7B). We did not attempt higher poly(I-C) concentrations, as
that could lead to responses that are not dependent on TLR3.
These results are consistent with the model that ODN2006 is a
more-potent antagonist of TLR3 signaling than poly(I-C) is an
agonist. Furthermore, it will be useful to examine further how
ssDNAs and poly(I-C) can compete for TLR3 binding.
Correlation between ssDNA binding to 3ECD and inhibition
of signaling. We characterized ligand binding by 3ECD by
using a pull-down assay in the presence of ssDNA competitor.
In this assay, biotinylated ODN2006 was bound to streptavidin
resin and incubated with a mixture of 3ECD and BSA to
provide an internal negative control. The assay is specific since
BSA present in each reaction mixture is not bound (Fig. 8A).
In addition, total yeast RNA was not able to prevent 3ECD
from binding ODN2006 (Fig. 8A, lane 9). Poly(I-C) (length,
200 bp) was unable to prevent ECD binding to ODN2006,
confirming that the ODN has higher affinity than poly(I-C)
(Fig. 8A, lane 3). In contrast, ssDNAs ODN2006, ODN2006c,
and ODN2216 that inhibited TLR3-specific reporter gene ac-
tivation by poly(I-C) were effective inhibitors of 3ECD binding
to ODN2006. The nonphosphorothioated 75-mer and dODN
that had reduced inhibitory activity or lacked TLR3-inhibiting
activity, respectively (Fig. 2B; Table 3), had reduced ability and
inability to inhibit 3ECD binding to the ODN2006-resin (Fig.
8A, lanes 7 and 8).
Using the competition assay, we compared the ability of
heterogeneous poly(I-C) to elute 3ECD bound to the
ODN2006-resin to that of ODN2006. Poly(I-C) added to the
reaction mixture at 168 to 333 g/ml was able to elute approx-
imately as much 3ECD as did 7.7 g/ml of ODN2006 (Fig. 8B,
compare lanes 4 and 5 to 8). These results are consistent with
our previous observation that 3ECD preferentially binds
ODN2006 over poly(I-C) (Fig. 7A). Furthermore, the experi-
ment yielded the same results when performed either on ice or
at room temperature.
To further extend the correlation between 3ECD ssDNA
binding and the effects on TLR3 activation of signal transduc-
tion, we tested equimolar amounts of a phosphorothioated
DNA that corresponds to the first 15 nucleotides of ODN2006,
named 06S, which had reduced ability to compete for 3ECD
binding to ODN2006 in vitro (Fig. 8C). Testing for its ability to
inhibit TLR3 activation of the NF-kB reporter in cells showed
that this activity was also reduced by a similar measure (Fig.
8D). All of these results demonstrate an excellent correlation
between ssDNA binding by 3ECD and the ability to inhibit
TLR3 activation of signaling. To summarize the results of all of
the experiments probing the mechanism of action of the
ssDNAs, we propose the following working model: ssDNAs
can bind to TLR3 and either directly or indirectly prevent
dsRNA binding. Furthermore, TLR3 in complex with ssDNA
FIG. 7. Examination of the interaction of 3ECD with poly(I-C) and
ODN2006. (A) Recombinant 3ECD binding to ODN2006 and poly(I-C)
in a UV-induced cross-linking (X-link) assay. ODN2006 and IC18 were
radiolabeled by a kinase reaction, and the autoradiograph is shown in the
upper panel. The lower panel contains a Coomassie (Cooma.) blue-
stained gel that is intended to allow normalization for the amount of
3ECD used in each reaction. The competitors (Comp.) used were mock
(), ODN2006, and heterogeneous poly(I-C). “M” corresponds to the
size marker. (B) ODN2006 is a potent inhibitor of TLR3 signaling even at
higher poly(I-C) concentrations. Since the experiment was performed
with different concentrations of ligands, the basal level of luciferase ac-
tivity is expected to change. Hence, the ratios of the levels of NF-B-
driven firefly luciferase to the levels of the putatively constitutive thymi-
dine kinase promoter are graphed. The level of induction is listed below
the graph. Note that there is a modest increase in TLR3 signaling at 10
and 20 g/ml of poly(I-C) in comparison to the level at 2.5 g/ml of
poly(I-C). The means of the results are shown above the bars, and the
error bars show standard errors of the means. pIC, poly(I-C); 2006,
ODN2006; , present; , absent.
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is unable to activate signaling, perhaps because ssDNA pre-
vents the proper oligomerization and/or conformational
changes that allow activation of the downstream adaptors.
ssDNA and cytokine production by BEAS-2B cells. To better
establish the physiological relevance of the ssDNA antagonists
of TLR3 signaling, we examined cytokine production in the
BEAS-2B cell line, which expresses native TLR3. BEAS-2B
cells produced an average of 1,500 pg/ml of interleukin-6
(IL-6) upon induction with 25 ng/ml poly(I-C) (Fig. 9A), an
amount 10-fold greater than that produced by the cells
treated with medium alone. The presence of ODN2006 or
ODN2006c alone did not induce cytokine production in the
absence of poly(I-C) (Fig. 9A). In the presence of 0.2 M
ODN2006 and poly(I-C), IL-6 levels were reduced to less than
200 pg/ml. The inhibitory effect of ODN2006 was also depen-
dent on its concentration (Fig. 9A). ODN2006c lacking the
CpG motif required to activate TLR9 had the same inhibitory
profile. Lastly, the same concentration-dependent inhibitory
effect was observed for four additional cytokines and chemo-
kines, IL-8, MCP-1, RANTES, and IP-10, that were previously
reported to be produced by BEAS-2B cells (Fig. 9B) (12).
Thus, the effects of ODN2006 in a bronchial epithelial cell line
are consistent with those from reporter assays with transfected
293T cells.
Inhibition of cytokine production in human PBMCs. To
extend our observations of the effects of ssDNAs, we examined
FIG. 8. ODN2006 is preferentially bound by TLR3. (A) An affinity pull-down assay was used to compare the binding of various ligands to
3ECD. The input used was a mixture of purified 3ECD and BSA. The mixture was then incubated with washed ODN2006-streptavidin resin in the
presence of the competitor nucleic acid shown above the gel image. All competitors were used at 3 g in the binding reaction mixtures. The gels
were stained with Coomassie blue. Proteins bound and not bound to the resin are shown in the upper and lower gel images. The identities of the
bands are shown to the right of the gel images. The binding reactions were performed at room temperature. (B) A comparison of the ability of
heterogeneous poly(I-C) to compete with ODN2006 for binding of 3ECD. All concentrations are shown as g/ml to facilitate comparisons.
(C) ssDNA 06S that is partially defective for inhibiting TLR3 signaling is also defective for preventing 3ECD binding to ODN2006-resin. All
competitors were added to the binding reaction mixture at 2 M. (D) Results of reporter assay demonstrating that 06S is defective for inhibiting
TLR3 signaling. The results are from the standard NF-	 reporter assay of HEK 293T cells transfected to express TLR3. The cells were induced
with poly(I-C) in the presence of the oligonucleotides at the concentrations shown. 2006, 2006c, and 2216 are ODNs. M, size marker; pIC,
poly(I-C); act., activity; S.E., standard error.
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PBMCs from six independent donors. The results from all of
the samples were consistent, and those from two are shown as
representative results (Table 5) Cells from both donors showed
little IFN- production when treated with the control medium
or with several ssDNAs (Table 5; data not shown). However, a
24-h treatment with poly(I-C) at 5 g/ml resulted in IFN-
levels of approximately 1,200 to 6,600 pg/ml.
Next, the effects of ssDNAs on IFN- production were ex-
amined with PBMCs from both donors. Along with poly(I-C)
at 5 g/ml, ODN2006 and ODN2006c at 1 M reduced IFN-
levels significantly and at 5 M reduced IFN- levels to back-
ground for both donors (Table 5). The effects of ODN2216 and
ODN2216c were more complex. IFN- production by PBMCs
from donor A was inhibited to background by all concentra-
tions of ODN2216 tested. The IFN- level was less sensitive to
ODN2216c, especially in donor B, although higher concentra-
tions of ODN2216 and ODN2216c did reduce IFN- produc-
tion. These results demonstrate that ssDNAs can inhibit IFN-
production to various degrees in PBMCs isolated from differ-
ent individuals.
To further extend the examination of the effects of ssDNAs,
the production of several cytokines and chemokines by human
PBMCs was quantified (Table 6). Of the 48 different samples
treated with ODNs at 5 M, only four did not reduce the levels
of IL-12, IL-1	, and MIG by at least 50% (Table 6). In the
absence of poly(I-C), only slight induction was seen for IL-12,
IL-1	, and MIG. However, the levels of IL-6 in response to the
ODNs were quite complex (see Fig. S2 in the supplemental
material). In the absence of poly(I-C), treatment with three of
the ODNs (2006, 2006c, and 2216) resulted in an increase in
IL-6 levels, while treatment with ODN2216c had no effect on
two of the PBMC samples and resulted in very high levels in
samples from two donors (see Fig. S2 in the supplemental
material). Treatment with poly(I-C) and ODN2216c did not
seem to further affect IL-6 levels except in two samples. Fur-
thermore, given that the ssDNAs lacking the CpG motif also
had effects, there is no correlation with activation of TLR9
signaling. These results demonstrate that while ssDNAs can
inhibit the production of cytokines and chemokines in human
cells in response to poly(I-C), there are differences associated
FIG. 9. ssDNA nucleotides can inhibit cytokine production in a human bronchial epithelial cell line, BEAS-2B. (A) Production of IL-6 with
increasing concentrations of ODN2006 and ODN2006c. IL-6 and other ILs were measured by using Luminex beads and antibodies specific to the
analyte. Poly(I-C) was added at 25 ng/ml in the samples whose results are shown with gray bars. “M” denotes the addition of unconditioned
medium. Error bars show standard errors of the means. PIC, poly(I-C). (B) A summary of the production of several cytokines and chemokines
in the presence of different concentrations of ODN2006 or ODN2006c in response to poly(I-C) treatment. The numbers in parentheses are the
values for 1 standard error. The numbers in bold indicate the samples in which treatment with an ODN decreased the poly(I-C) induction of the
cytokine or chemokine by 50%. The underlined numbers are values obtained with poly(I-C), 2006, and 2006c as the ligands. pIC, poly(I-C); UD,
undetected.
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with the ssDNA sequence and, possibly, with the genotypic
differences of the donors. We further note that IL-6 produc-
tion in BEAS-2B cells was repressed in a concentration-depen-
dent manner (Fig. 9A). While we do not understand these
differences, we speculate that there are several receptors that
can respond to dsRNA (1). The distribution of these receptors
may also differ between cell types, and it is possible that cross
talk between them could result in the more-complex cytokine
pattern observed in human PBMCs. These downstream events
are likely quite complex and should be the objective of a future
study.
Summary and final comments. We have demonstrated that
several ssDNAs can inhibit TLR3-specific activation of the
NF-B reporter gene in 293T cells but do not affect TLR9 or
TLR4. The inhibitory effects are also observed in cultured
human bronchial epithelial cells and in human PBMCs that
natively express TLR3 and can respond to poly(I-C). In terms
of the mechanism of action, the ssDNAs can bind to purified
3ECD in vitro with higher apparent affinity than with poly(I-C)
and colocalize with TLR3 in cells. There is also a strong cor-
relation between ssDNA binding and inhibition of TLR3 ac-
tivity. Whether the ssDNAs bind to the same location as
poly(I-C) within 3ECD remains to be determined.
It is possible that ssDNAs with the ability to inhibit TLR3
could also act on other innate immune receptors and/or nucleic
acid binding proteins to affect other signaling pathways. In fact,
there is precedent for ssDNAs to affect the responses of TLRs.
CpG-containing DNAs could activate STAT1 and IFN-	 in
mouse macrophage and dendritic cells (35). In addition, oligo-
nucleotides consisting of homothymidines inhibited TLR7-spe-
cific signaling that was induced with Resiquimod (18, 19). Dorn
et al. (11) had reported that oligonucleotides that lack CpG
motifs could suppress IL-8 production in human keratinocytes.
The oligonucleotides in their assay required phosphorothio-
ates and accumulated in perinuclear regions of the cells. We
have also observed a suppression of IL-8 production in poly(I-
C)-stimulated BEAS-2B cells (Fig. 9), but phosphorothioates
are not absolutely required for oligonucleotides to have inhib-
itory activity in 293T cells and the ssDNAs accumulated pri-
marily in vesicles.
It is important to note that the TLR3-modulating ssDNAs
include ones that are unable to function as potentiators or
antagonists to TLR9. First, TLR9 expression is not detectable
in HEK 293T cells. Second, a CpG motif is not required for the
ssDNAs to have inhibitory activity. Third, blocking groups at
the 5 terminus of ODN2006 that abolish TLR9 activation did
not affect the inhibitory activity against TLR3. It remains to be
determined whether other innate receptors respond to these
ssDNAs and perhaps contribute to the complex response of
cytokine levels in human PBMCs. We do note that TLR4
signaling was not apparently affected by ODNs in 293T cells
(Fig. 1D), suggesting that there is some specificity in the effects
of ODNs on TLR3. All of the results from localization studies,
binding studies using purified human 3ECD, and competition
studies with reporter constructs consistently support a model
where the ssDNAs bind to one or more sites in the 3ECD and
prevent activation by poly(I-C). While TLR3 activation re-
quires poly(I-C)s of lengths in excess of 40 bp, ODN2006 is
only 24 nucleotides long. In addition, a derivative of ODN2006
of 15 nucleotides, 06S, can reduce TLR3 signaling by half when
added to the medium of 293T cells at approximately 2 M
(Fig. 8D). A modified ssDNA of 15 to 24 nucleotides may not
be able to span oligomers of TLR3, suggesting that the
ssDNAs bind to TLR3 monomers. One possible outcome of
this binding is the inhibition of TLR3 oligomerization. Modu-
TABLE 6. Summary of the effects of four ssDNAs on cytokine production
Treatment
Amt (pg/ml) of cytokine produced by PBMC of each donora
IL-12 IL-1	 MIG
A B C D A B C D A B C D
Poly(I-C) 4,858 8,756 4,743 4,220 549 421 303 316 903 1,035 580 317
Poly(I-C) plus ODN2006 85 128 95 74 28 447 34 39 47 49 21 35
Poly(I-C) plus ODN2006c 78 224 104 94 118 191 104 83 49 47 23 34
Poly(I-C) plus ODN2216 1,150 1,991 701 105 145 237 112 55 603 376 68 39
Poly(I-C) plus ODN2216c 151 231 234 97 126 165 242 81 74 61 33 36
Medium 23 60 37 34 21 25 24 32 34 38 7 29
Medium plus ODN2006 57 125 82 67 27 77 32 39 38 45 16 34
Medium plus ODN2006c 76 119 79 91 112 46 74 82 49 43 22 35
Medium plus ODN2216 86 123 114 69 31 80 42 45 82 87 28 36
Medium plus ODN2216c 105 117 135 96 123 39 105 65 68 46 30 37
a The numbers in bold show samples for which treatment with 5 M ssDNA reduced cytokine production by more than 50%.
TABLE 5. Effects of ssDNAs on IFN- production by PBMCs
isolated from human donorsa
ODN Concn(M)
IFN- production (pg/ml) of PBMCs treated with:
Mock (n  6) Poly(I-C) (n  6)
Range Mean Range Mean %
Mock 1–27 14 1,160–6,674 4,214 100
2006 1 ND 11–1,842 579 14
5 1–42 25 6–56 31 1
2006c 1 ND 1–195 72 2
5 1–56 25 13–95 44 1
2216 1 ND 82–2,681 1,447 34
5 4–64 38 55–631 287 7
2216c 1 ND 56–4,483 1,887 45
5 16–135 53 25–3,266 1,278 30
a Effects of two concentrations of ssDNAs on IFN- production from six
donors. Poly(I-C) was used at 5 g/ml. ND, not done.
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lation of signaling by an innate receptor could be important
in disease outcomes, an example being the frequent bacte-
rial infections of influenza patients that often exacerbate
disease symptoms (5).
An intriguing property of the ssDNAs is that their inhibitory
activity can differ according to their number of phosphorothio-
ates, length, and also, base sequence. While further work is
necessary to produce ssDNAs with improved specificity, this
class of molecules holds promise for studies of signaling from
the innate immune receptors and for modulating cytokine re-
sponses, perhaps in combination with the use of monoclonal
antibodies specific to TLR3 (12).
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